IL4 and atopic eczema: In vivo, BV treatment significantly reduced phthalic anhydride-induced atopic dermatitis clinical score, back and ear epidermal thickness, and the lymph node weight, decreased the level of IgE, IL-4, IL-13, TNF-α, IL-1β, and IL-6 and the number of eosinophil, neutrophil, monocytes, mast cells, F4/80-positive cells and Ly6G-positive cells, as well as inhibited the iNOS and COX-2 expression and activated MAPK and NF-κB in the skin tissues.